Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CGUB17077 / PRIME / Edward Messing

Research Question:
What are the good and bad effects of using the Tokyo-172 version of BCG with the currently used BCG LIVE (TICE® BCG) version on people with bladder cancer receiving BCG in the bladder and what are the good and bad effects of adding a BCG vaccination (given under the skin) in addition to placing BCG in only the bladder?

Basic Study Information

Purpose:
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Location: Cancer Center - Urology
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03091660?term=S1602&rank=1
Study Reference #: CGUB17077

Lead Researcher (Principal Investigator)

Lead Researcher:  Edward Messing

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search